HIK LSE Week ended 07 Aug 2026

Weekly Investor Report

Hikma Pharmaceuticals PLC · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 1,677 GBP
5.8% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 14.1% above the Trend Line and sits at 64.3% of its 52-week range. The latest completed week returned 5.8%, after a 5.9% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers. The latest news-sentiment score is 55/100.

Setup score 57 out of 100
Latest Close 1,677 GBP 7 Aug 2026
1W Return 5.8% latest completed week
4W Return 5.9% short-term follow-through
12W Return 16.5% quarterly tape
Trend Breadth 5.8% 3 of 52 weeks active
Volume Ratio 2.0x vs 13-week average
What is working
  • The trend backdrop is active with a 3-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 5.8% Latest completed week; four-week move 5.9%. Indicator stack 14/77 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 55/100 22 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 14.1% above the Trend Line and sits at 64.3% of its 52-week range. The latest completed week returned 5.8%, after a 5.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5212-week average 0.29

12-week confirmation

Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.52Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 5.9% over four weeks, 16.5% over 12 weeks, and -13.5% over one year. The current trend has remained active for 3 consecutive weeks.

Performance by holding period

1W5.8%
4W5.9%
12W16.5%
26W9.7%
52W-13.5%
Active trend streak3 weeks
Active weeks in one year3
Trend breadth5.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.35Latest activity-pressure read.
Pressure change31.3%Four-week change in activity pressure.
Leadership-1.26Latest relative-leadership reading.
RS change80.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Dec 2025 Field coverage 91% Model confidence 72%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value93/100Relative valuation strength. Underlying universe rank 8; rank 1 is best.
Quality16/100Profitability and accounting quality. Underlying universe rank 85; rank 1 is best.
Momentum7/100Medium-term price momentum. Underlying universe rank 94; rank 1 is best.
Growth82/100Revenue and earnings growth. Underlying universe rank 19; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework82/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
8.7x
Price divided by trailing earnings.
Price / sales
1.0x
Market value relative to trailing revenue.
EV / EBITDA
5.8x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
43.0%
Gross profit retained from each unit of revenue.
Operating margin
18.9%
Operating profit retained from revenue.
Free-cash-flow margin
3.6%
Free cash flow generated from revenue.
Return on invested capital
11.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
7.1%
Latest one-year revenue growth.
EPS growth
12.1%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-63.8%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.7%
Cash dividends relative to market value.
Buyback yield
1.0%
Net share repurchases relative to market value.
Shareholder yield
4.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment55/100

Weighted news tone is neutral across 22 relevant articles.

2 positive · 20 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-14.0%Distance below the 52-week high.
13-week volatility2.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher20 of 266 weeks finished lower.
Best week+5.8%Week of 7 Aug.
Worst week-19.5%Week of 27 Feb.
Latest week+5.8%Week of 7 Aug.

Shape of recent returns

Strong gains4
Modest gains16
Flat weeks0
Modest losses4
Sharp losses2
Recent vol2.1%13-week weekly-return volatility.
Base vol4.7%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew2.6% / -3.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape50/100

Trend, activity pressure, participation, and risk combine to a 50/100 tape read.

 Indicator analysis45/100

Latest 12-week confirmation: trend 3/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.52; No reversal markers Factors42/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 31 SVQF82/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 47.5 of 260 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment55/100

Weighted news tone is neutral across 22 relevant articles.

Berenberg Bank Forecasts Strong Price Appreciation for Hikma Pharmaceuticals (LON:HIK) Stock Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20261,677 GBP5.8%1,470 GBP1,828 GBP1.35-1.266.9MOn
31 Jul 20261,585 GBP0.2%1,465 GBP1,831 GBP1.39-7.084.6MOn
24 Jul 20261,582 GBP1.3%1,463 GBP1,834 GBP1.31-6.956.0MOn
17 Jul 20261,561 GBP-1.5%1,461 GBP1,837 GBP1.17-7.865.1MOff
10 Jul 20261,584 GBP2.3%1,459 GBP1,838 GBP1.03-6.407.3MOff
3 Jul 20261,548 GBP1.1%1,459 GBP1,840 GBP0.85-10.86596.3KOff
26 Jun 20261,531 GBP5.1%1,460 GBP1,842 GBP0.73-11.30223.7KOff
19 Jun 20261,457 GBP-1.6%1,462 GBP1,844 GBP0.69-15.301.7MOff
12 Jun 20261,480 GBP0.6%1,466 GBP1,847 GBP0.65-15.83323.3KOff
5 Jun 20261,471 GBP-0.3%1,469 GBP1,850 GBP0.55-16.46421.3KOff
29 May 20261,476 GBP1.2%1,481 GBP1,852 GBP0.48-17.464.2MOff
22 May 20261,459 GBP1.3%1,491 GBP1,855 GBP0.31-19.724.2MOff
15 May 20261,440 GBP1.6%1,501 GBP1,857 GBP0.10-19.543.3MOff
8 May 20261,418 GBP0.7%1,513 GBP1,860 GBP-0.10-21.883.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context